菜单

CRO Services

Drug Development Expertise Empowering Research Services for Biologics

 

 

Early-stage biologics discovery often prioritizes binding affinity but overlooks critical developability factors, leading to CMC and clinical challenges. This webinar introduces the Micro Developability platform, a high-throughput analytical suite that requires <1 mg of antibody per assay to assess key developability attributes like sequence liability, PK and stability. Through case studies, we will illustrate how these early assessments optimize leads, mitigate downstream risks, and facilitate a smooth transition to CMC.

 

You will gain valuable insight into:

 

High-throughput assays with robust performance and high sensitivity for biophysical and PK profiling, including AC-SINS, BVP/DNA/insulin ELISA, FcRn affinity and serum stability

Integrated developability assessments combining in silico modeling and in vitro assays to identify potential risks in early stage

Micro-developability strategy for new modalities

 

Speaker:

 

Lei Guo, Ph.D., Senior Director, CRO Services 

 

[WEBINAR RECORDING] Early-Stage Developability Assessment for Lead Optimization

 

Discuss Your Protein Characterization Projects

Please complete the form on the following page to connect with our experts.

Connect with our Experts